NewcelX Ltd./$NCEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NewcelX Ltd.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
- Ticker
- $NCEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11
- Headquarters
- Kloten, Switzerland
- Website
- newcelx.com
NewcelX Ltd. Metrics
BasicAdvanced
$16M
-
-$0.51
-
-
Price and volume
Market cap
$16M
52-week high
$5.12
52-week low
$1.83
Average daily volume
20K
Financial strength
Current ratio
0.397
Quick ratio
0.208
Total debt to equity
0.065
Profitability
EBITDA (TTM)
-3.979
Management effectiveness
Return on assets (TTM)
-49.59%
Return on equity (TTM)
-1.22%
Valuation
Price to book
2.5
Price to tangible book (TTM)
-7.08
Price to free cash flow (TTM)
-2.911
Free cash flow yield (TTM)
-34.35%
Free cash flow per share (TTM)
-0.962
Growth
Earnings per share change (TTM)
-92.82%
3-year earnings per share growth (CAGR)
-30.36%
10-year earnings per share growth (CAGR)
-34.53%
NewcelX Ltd. Financial Performance
Revenues and expenses
NewcelX Ltd. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.